Multicenter Phase II Trial of Durvalumab (MEDI4736) with Trastuzumab and Pertuzumab Combination in HER2-Enriched and HER2-Amplified Breast Cancer (DTP Trial)
Latest Information Update: 12 Mar 2025
At a glance
- Drugs Durvalumab (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Early breast cancer
- Focus Therapeutic Use
- Acronyms DTP
Most Recent Events
- 10 Mar 2025 Planned End Date changed from 1 Feb 2025 to 1 Dec 2025.
- 10 Apr 2024 Status changed from recruiting to active, no longer recruiting.
- 10 Apr 2024 Results assessing efficacy of chemotherapy-free neoadjuvant regimen with DTP in HER2-enriched early breast cancer presented at the 115th Annual Meeting of the American Association for Cancer Research.